Kyverna Therapeutics (KYTX) EBITDA (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of EBITDA data on file, last reported at -$39.9 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 10.77% year-over-year to -$39.9 million; the trailing twelve-month figure through Mar 2026 stood at -$158.0 million (down 6.12% YoY), and the FY2025 full-year result was -$169.8 million, down 19.09% from the prior year.
• EBITDA for Q1 2026 stood at -$39.9 million, down from -$39.3 million in the prior quarter.
• Across five years, EBITDA topped out at -$11.1 million in Q1 2023 and bottomed at -$44.7 million in Q1 2025.
• The 4-year median for EBITDA is -$34.3 million (2024), against an average of -$30.4 million.
• The widest annual swing landed in 2024, when EBITDA tumbled 139.98%; it then advanced 10.77% in 2026.
• A 4-year view of EBITDA shows it stood at -$21.4 million in 2023, then slumped by 91.99% to -$41.0 million in 2024, then grew by 4.29% to -$39.3 million in 2025, then declined by 1.63% to -$39.9 million in 2026.
• The last three EBITDA figures came in at -$39.9 million (Q1 2026), -$39.3 million (Q4 2025), and -$36.7 million (Q3 2025), per Business Quant data.

Peer Comparison